Edit ModuleShow Tags Edit ModuleShow Tags

FDA significantly restricts access to the diabetes drug Avandia



Published:

09-23-2010] The U.S. Food and Drug Administration announced that it will significantly restrict the use of the diabetes drug Avandia (rosiglitazone) to patients with Type 2 diabetes who cannot control their diabetes on other medications. These new restrictions are in response to data that suggest an elevated risk of cardiovascular events, such as heart attack and stroke, in patients treated with Avandia.

Summary of Decision
Edit Module

Add your comment: